Predictors of cardiovascular events in patients with end-stage renal disease: An analysis from the Fosinopril in Dialysis study

Nephrology Dialysis Transplantation

Volumn 22, Issue 12, 2007, Pages 3573-3579

  Kessler, Michèle ^a,g   Zannad, Faiez ^a   Lehert, Philippe ^b,h   Grünfeld, Jean Pierre ^c   Thuilliez, Christian ^d   Leizorovicz, Alain ^e   Lechat, Philippe ^f  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Faculty of Medicine   (Australia)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CHU NANCY BRABOIS   (France)

^h Louvain Academy   (Belgium)

Author keywords

Cardiovascular disease; End stage renal disease; Morbidity; Mortality

Indexed keywords

C REACTIVE PROTEIN; FOSINOPRIL;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STROKE; STRUCTURAL EQUATION MODELING; UNSTABLE ANGINA PECTORIS;

AGED; CARDIOVASCULAR DISEASES; FEMALE; FOSINOPRIL; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK FACTORS;

EID: 36749072988     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm417     Document Type: Article

References (21)

1. US Renal Data System. USRDS 2004 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2004
2. Couchoud C, Stengel B, Landais P et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 2006; 21: 411-418
3. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44: 16-21
4. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007; 11: 1-14
5. deFilippi C, Wasserman S, Rosanio S et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353-359
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031
7. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084
8. Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G. Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002; 24: 175-186
9. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16 [Suppl 1]: S83-S88
10. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774
11. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
12. Joreskog K. Testing structural equation models. In: Bollen K, Long J, eds. Testing Structural Equation Models. Sage: Newbury Park, London 1993; 294-316
13. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
14. Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588
15. Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577
16. Zager PG, Nikolic J, Brown RH et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54: 561-569
17. Port FK, Hulbert-Shearon TE, Wolfe RA et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517
18. Iseki K, Miyasato F, Tokuyama K et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997; 51: 1212-1217
19. London GM. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant 2001; 16: 475-478
20. Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228
21. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019